Symptoms, Diagnosis, Prognosis and Management of Long COVID or Post-COVID Conditions, 2nd Edition

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Clinical Diagnosis and Prognosis".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 712

Special Issue Editor

Special Issue Information

Dear Colleagues,

Newly developed neurological, psychiatric, pulmonary, vascular, renal, and cardiac symptoms and disorders have been reported months after SARS-CoV-2 infection has been resolved. The SARS-CoV-2 virus can directly damage major organs, which can trigger clinical disorders. Indirect insults secondary to the viral infection (such as respiratory distress, sepsis and other co-infections, inflammation, and over-reactive host immune responses) could also cause further damage. Persistent damage to organs such as the lungs, kidneys, heart, and liver after SARS-CoV-2 infection has been reported in some COVID-19 survivors. SARS-CoV-2 infection could also trigger new onset or accelerate the worsening of pre-existing conditions such as diabetes, hypertension, and pulmonary and neurological disorders. The sheer number of COVID-19 patients suggests that long COVID will likely burden healthcare systems for years.

We invite you to contribute to this timely and exciting Special Issue on “Symptoms, Diagnosis, Prognosis and Management of Long COVID or Post-COVID Conditions, 2nd Edition”. We thank you for your time and look forward to receiving your contributions.

Prof. Dr. Tim Duong
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • long COVID
  • SARS-CoV-2
  • COVID-19 sequela
  • post-acute sequelae of COVID-19 (PASC)
  • COVID-19 symptoms
  • multiorgan failure
  • diabetes
  • hypertension
  • shortness of breath
  • symptoms
  • diagnosis
  • prognosis
  • management

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1090 KiB  
Article
Long-Term Outcomes of Patients with Pre-Existing Essential Tremor After SARS-CoV-2 Infection
by Rachel Pakan, Roham Hadidchi, Yousef Al-Ani, Hannah Piskun, Katie S. Duong, Sonya Henry, Stephen Wang, Carine W. Maurer and Tim Q. Duong
Diagnostics 2024, 14(24), 2774; https://doi.org/10.3390/diagnostics14242774 - 10 Dec 2024
Viewed by 600
Abstract
Background/Objectives: Although COVID-19 has been linked to worse outcomes in patients with neurological disorders, its impact on those with essential tremor (ET) remains unclear. To investigate clinical outcomes of ET patients with and without COVID-19 three and a half years post-pandemic. Methods: 1074 [...] Read more.
Background/Objectives: Although COVID-19 has been linked to worse outcomes in patients with neurological disorders, its impact on those with essential tremor (ET) remains unclear. To investigate clinical outcomes of ET patients with and without COVID-19 three and a half years post-pandemic. Methods: 1074 ET patients were evaluated in this retrospective study in the Montefiore Health System from January 2016 to July 2023. Comparisons between ET patients with and without a positive SARS-CoV-2 polymerase chain reaction test were made. Outcomes included post-index date major adverse cardiovascular events (MACEs), new-onset sleep disturbances, fatigue, dyspnea, first-time fall, new-onset anxiety, new-onset depression, headache, new-onset imbalance, new-onset mild cognitive impairment, and all-cause mortality, adjusted hazard ratios (aHR) adjusting for covariates were calculated. Results: ET patients with COVID-19 had higher prevalence of pre-existing type-2 diabetes, depression, and anxiety compared to ET patients without COVID-19. COVID-19 was significantly associated with higher risk of MACEs, (aHR = 2.39 [1.49, 3.82]), new-onset sleep disturbance, (aHR = 2.12 [1.44, 3.13]), fatigue, (aHR = 1.83 [1.27, 2.65]), dyspnea, (aHR = 1.98 [1.40, 2.80]), first-time fall, (aHR = 4.76 [2.24, 10.14]), new-onset anxiety, (aHR = 3.66 [2.02, 6.64]), and new-onset depression, (aHR = 2.38 [1.20, 4.70]). COVID-19 was not associated with all-cause mortality. Conclusions: In patients with ET, COVID-19 significantly increases the risk of several long-term adverse health outcomes, but not mortality. Full article
Show Figures

Figure 1

Back to TopTop